Intermediate Dose of Intravenous Melphalan in Advanced Multiple Myeloma
| Autor: | K. Papanastasiou, Alice Maniatis, S Tsakanikas, M. Stamatelou |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Male
Melphalan Cancer Research medicine.medical_specialty Vincristine medicine.medical_treatment Urology Dexamethasone Refractory hemic and lymphatic diseases Antineoplastic Combined Chemotherapy Protocols medicine Humans Multiple myeloma Chemotherapy business.industry General Medicine medicine.disease Surgery Oncology Bone marrow suppression Doxorubicin Toxicity Female Multiple Myeloma business medicine.drug |
| Zdroj: | Oncology. 48:369-371 |
| ISSN: | 1423-0232 0030-2414 |
| DOI: | 10.1159/000226961 |
| Popis: | Eighteen patients with advanced multiple myeloma resistant to VAD chemotherapy (vincristine, Adriamycin, dexamethasone) were treated with intravenous melphalan in a single-pulse dose of 50-70 mg/m2. Objective response (greater than or equal to 50% reduction of the monoclonal protein) was observed in 9 patients. The median duration of remission in the responding patients was 6 months and the median survival 11.5 months. The main toxicity noted was bone marrow suppression. We conclude that intermediate doses of intravenous melphalan are a useful therapeutic modality in refractory or relapsing myeloma patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|